Key Performance Indicators
PRIMARY
Hazard Ratio (Death)
0.76
95% CI: 0.63–0.93
24% reduction in risk of death
PRIMARY
Median OS Gain
+12.5
Months
Clinically meaningful extension
6-Year Survival Rate
44.2%
vs 32.0% Placebo
Long-term benefit sustained
01
Survival advantage widens over time, reaching a 12% absolute difference at 6 years
Kaplan-Meier estimates show the separation of survival curves becomes more pronounced with extended follow-up.
02
Ribociclib extends median overall survival to over 5 years
Comparison of median overall survival times shows a clear shift in longevity for the treatment arm.
03
Survival benefit is consistent across key prognostic subgroups
Hazard ratios favor Ribociclib (<1.0) across stratification factors, including difficult-to-treat visceral metastases.
04
Treatment delays the need for cytotoxic chemotherapy by nearly a year
Patients on Ribociclib maintained chemotherapy-free status significantly longer than those on Placebo.
05
Neutropenia is the primary toxicity, while other severe events remain uncommon
Comparison of Grade 3 or 4 adverse events of special interest.
06
Subsequent CDK4/6 inhibitor use was higher in the placebo arm
Despite 34% of placebo patients receiving CDK4/6 inhibitors post-progression, the Ribociclib arm maintained an OS advantage.
Editorial Conclusion
“Ribociclib plus letrozole demonstrates a statistically significant and clinically meaningful overall survival benefit of over 12 months compared to letrozole alone in first-line advanced breast cancer.”
Median OS reached 63.9 months, the longest reported in this setting to date.
Benefit was consistent across subgroups and maintained despite high crossover to CDK4/6 inhibitors in the control arm.
The treatment also significantly delayed the time to first chemotherapy.
Clinical Implication
These findings support Ribociclib plus Letrozole as a standard-of-care first-line treatment for postmenopausal women with HR+, HER2- advanced breast cancer.
Sources & Abbreviations
Abbreviations
| Abbrev | Meaning |
|---|---|
| OS | Overall Survival |
| HR | Hazard Ratio |
| CI | Confidence Interval |
| CDK4/6 | Cyclin-dependent kinases 4 and 6 |
Source
N Engl J Med 2022;386:942-50
DOI: 10.1056/NEJMoa2114663
Limitations
- Black patients were underrepresented (2.5%).
- High rate of subsequent CDK4/6 inhibitor use in placebo arm required statistical adjustment (RPSFT model) to estimate true effect size.